Wedbush restated their outperform rating on shares of Inozyme Pharma (NASDAQ:INZY – Free Report) in a report issued on Monday, RTT News reports. Wedbush currently has a $15.00 price objective on the stock. Separately, HC Wainwright restated a buy rating and set a $16.00 target price on shares of Inozyme Pharma in a research note […]
Related Keywords
Inozyme Pharma , Douglasa Treco , Schonfeld Strategic Advisors , Securities Exchange Commission , Inozyme Pharma Inc , Inozyme Pharma Company Profile , Eventide Asset Management , Free Report , Get Free Report , Exchange Commission , Capital Partners , Strategic Advisors , Capital Management , Asset Management , Inozyme Pharma Daily , Nasdaq Inzy , Minzy , Medical , Reiterated Rating , Wedbush ,
comparemela.com © 2020. All Rights Reserved.